Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15240168 | 0.78 | CHRM5 (0.40) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL168722 | 0.78 | CHRM2 (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL9590421 | 0.76 | HTR2A (0.38) | HTR2AHTR2CSLC6A4SLC6A3 | |
| SCHEMBL21009725 | 0.73 | HTR2A (0.33) | HTR2AHTR2CKMT2A | |
| SCHEMBL26998904 | 0.73 | DAO (0.38) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL21962777 | 0.71 | CA2 (0.39) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL14709145 | 0.71 | — | — | |
| SCHEMBL24364000 | 0.70 | PARP1 (0.42) | F2CHRNB2CHRNA7CHRNA4MEN1 | |
| SCHEMBL27869187 | 0.70 | ALDH1A1 (0.43) | F2HTR2AHTR2CL3MBTL1MEN1 | |
| SCHEMBL6179170 | 0.69 | CHRM5 (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | US | disclosed |
| WO-2009126635-A1 | 2-AMINO-BENZOTHIAZOLE DERIVATES USEFUL AS INHIBITORS OF ROCK KINASES | ABBOTT LABORATORIES (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258907-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ROCK KINASES | ROCK1, ROCK2, RHOA | CHRM5 864/4885CHRM3 583/4885CHRM2 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.